# US 2020/0002728 A1 · Method for Cell Line Development

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002728 A1
- Document ID: US20200002728A1
- Status: Published application
- Kind: A1
- Application number: 16/490,623
- Filed: 2018-02-23
- Published: 2020-01-02
- Earliest claimed: 2017-03-03
- Assignees: GE Healthcare Bio-Sciences AB
- Applicants: GE Healthcare Bio-Sciences AB
- Inventors: Daniel Ivansson; Andreas Castan
- Web page: https://patentgrep.com/patent/US20200002728A1

## CPC

- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/907: {in mammalian cells}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/67: General methods for enhancing the expression
- C12N 15/85: for animal cells
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12N 2510/02: Cells for production
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to an improved method for cell line development (CLD) which is generally applicable to production of any therapeutic protein that can be produced using mammalian Cell lines and in particular Chinese Hamster Ovary (CHO) cells. The method combines site-directed integration (SDI), expression construct components improving the post-transcriptional processing of the gene of interest (GOI) and the introduction of a onetime pre-CLD host cell line selection workflow to generate a production competent cell line that can then be used in multiple CLD efforts using SDI from that point on.

## Claims

### Claim at position 1

-23. (canceled)

### Claim 24

A method to obtain a cell suitable for expressing protein comprising the following steps:
a. integration of a nucleic acid molecule encoding a first protein of interest into a pre-defined site in the genome of a recipient cell;
b. identification of cells expressing the first protein of interest;
c. excision of the nucleic acid sequence encoding the first protein of interest from the genome of the identified cells; and
d. integration of a nucleic acid molecule encoding a second protein of interest into the genome of the identified cell.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the second protein of interest is integrated into said pre-defined site in the genome.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the second protein of interest is integrated into a second pre-defined site in the genome.

### Claim 27 (depends on 24)

The method of claim 24, further comprising creation of a cell line suitable for production of said second protein of interest as a recombinant protein.

### Claim 28 (depends on 27)

The method according to claim 27, further comprising providing the recombinant protein as an active pharmacological ingredient.

### Claim 29 (depends on 27)

The method according to claim 27, further comprising providing the recombinant protein as an ingredient in a diagnostic reagent.

### Claim 30 (depends on 27)

The method according to claim 27, further comprising providing the recombinant protein as a reagent in an industrial process.

### Claim 31 (depends on 24)

The method according to claim 24, wherein the first protein of interest is a fluorescent protein.

### Claim 32 (depends on 24)

The method according to claim 24, wherein the first protein of interest is an immunoglobulin or immunoglobulin-like protein.
